Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation

TR Therapeutics12 enrolled

Overview

Study is intended to evaluate safety and efficacy parameters in patients treated with GLYC-101 gel or placebo after laser ablation.

The proposed pilot-study will document feasibility, safety and efficacy of topically applied Glucoprime gel (GLYC-101 gel 1.0 %) in promoting wound healing in healthy volunteer subjects undergoing retro-auricular Carbon Dioxide Laser Skin Resurfacing (CO2 LSR). The study will observe the effects of the topical agent over the course of 1 month following the treatment. as a preparation for study GLYC-101-1b (Double-blind, randomized, placebo-controlled Phase 2 Pilot Study to investigate the safety and efficacy of 1.0 % topically applied GLYC 101 compared to placebo, in patients undergoing Carbon Dioxide Laser Skin Resurfacing).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Wounds

Interventions

Placebo gelDRUG

Administration of Placebo gel on Day 1, 3 and 5 post ablation.

GLYC-101 gel (1.0 %)DRUG

Administration on Day 1, 3 and 5 post laser ablation.

Eligibility

Sex: ALLMin age: 25 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Subjects meeting all of the following criteria will be considered for admission to the study: * Patients giving informed consent for retro-auricular laser ablation between 25 and 55 years old. * Retro-auricular area is free of any irritation, scars or dermatologic conditions which might interfere with the study. * Willing and able to participate in the study and follow all study directions. * Able to read, understand and sign the consent form. Exclusion Criteria: * Pregnant, nursing, or planning a pregnancy during the course of the study, as determined by the interview and a urine pregnancy test. * Systemic or cutaneous disease that may interfere with the study results. * Presence of irritation or dermatologic skin conditions in the retro-auricular area. * Known allergies to materials within the test formulations. * Systemic or cutaneous therapy with medication that impacts wound healing (steroids, immune modulators, immune suppressants).

Locations (1)

CLINICAL TESTING CENTER of BEVERLY HILLS

Beverly Hills, California, United States

Outcomes

Primary Outcomes

Time to Complete Wound Closure (Epithelialization)

Subjects were evaluated every 2 days from the time of the laser procedures for the first 10 days and then seen every 2 weeks for 4 weeks. Efficacy was assessed based on the time to complete epithelialization in terms of the number of days from Day 1 (day of laser ablation) to the day on which complete epithelialization was observed.

Time frame: Over the course of 1 month following the initial treatment.

Secondary Outcomes

Percentage of Wound Epithelialized

The percentage of wound epithelialized was assessed at Day 15 post laser ablation.

Time frame: Day 15 post laser ablation.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.